Informations générales (source: ClinicalTrials.gov)
Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced Non-small Cell Lung Cancer Patients (NSCLC) (CIRCULAR)
Interventional
N/A
Institut Bergonié (Voir sur ClinicalTrials)
janvier 2022
janvier 2026
29 juin 2024
Multicenter prospective cohort study aiming to evaluate the detection rate of EGFR gene
mutation in patients with advanced NSCLC in a real-word clinical setting, based on liquid
biopsy and tissue analyses.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | Catherine DANIEL, Dr | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHRU Lille - 59037 - Lille - France | Alexis CORTOT, Pr | Contact (sur clinicalTrials) | |||
| CHU de Rennes - Hopital Pontchaillou - 35033 - Rennes - France | Hervé LENA, Dr | Contact (sur clinicalTrials) | |||
| CHU Nice-Hopital de Cimiel - 06000 - Nice - France | Paul HOFMAN, Pr | Contact (sur clinicalTrials) | |||
| CHU Poitiers - 86021 - Poitiers - France | Clotilde DELDYCKE, Dr | Contact (sur clinicalTrials) | |||
| CHU Strasbourg - 67091 - Strasbourg - France | Michèle BEAU-FALLER, Pr | Contact (sur clinicalTrials) | |||
| Hospices Civils de Lyon - 69002 - Lyon - France | Sébastien COURAUD, Pr | Contact (sur clinicalTrials) | |||
| Institut Bergonie - 33076 - Bordeaux - France | Sophie COUSIN, Dr | Contact (sur clinicalTrials) | |||
| Institut de Cancérologie de l'Ouest - Site Paul Papin - 49000 - Angers - France | Alain MOREL, Pr | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Male or female patients aged ≥ 18 years at time of proposal study,
2. Histologically confirmed non-small cell lung carcinoma,
3. No previous treatment for NSCLC,
4. Indication to EGFR status determination following HAS recommendation,
5. Voluntary signed and dated written informed consent prior to any study specific
procedure
6. Patients with a social security in compliance with the French Law.
1. Male or female patients aged ≥ 18 years at time of proposal study,
2. Histologically confirmed non-small cell lung carcinoma,
3. No previous treatment for NSCLC,
4. Indication to EGFR status determination following HAS recommendation,
5. Voluntary signed and dated written informed consent prior to any study specific
procedure
6. Patients with a social security in compliance with the French Law.
1. Treatment for advanced NSCLC started before liquid biopsy sampling.
2. Involvement in the planning and/or conduct of the study (applies to both
Investigator staff and/or staff at the study site).